IPO registrations (S-1, F-1) · Registrants
INTENSITY THERAPEUTICS, INC.
- SEC CIK
- 1567264 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2021-10-28, last 2025-04-24; 3 initial registrations, 17 amendments
- Outcome
- Final prospectus filed 2023-06-30; declared effective 2023-06-29
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 1 ENTERPRISE DRIVE, SUITE 430, Shelton, CT 06484
- EIN
- 46-1488089
- Ticker
- INTS (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- INTENSITY THERAPEUTICS, INC. on the corporate pages
Offering terms
- Proposed price range
- $4.00–$5.00 per share (S-1/A filed 2023-06-23)
- Final price
- $4.00 per share, within the range (424B4 filed 2023-06-30, an initial public offering)
- Shares sold
- 3,900,000
- Gross proceeds
- $15,600,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol INTS
- Lead underwriters
- The Benchmark Company
- Syndicate
- Freedom Capital Markets
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: INTENSITY THERAPEUTICS, INC. Fuzzy (name and state)
- Business registration: INTENSITY THERAPEUTICS LLC Fuzzy (name and state)
- Form 5500 plan sponsor: INTENSITY THERAPEUTICS INC EXACT (EIN (EXACT))
- Form D issuer: INTENSITY THERAPEUTICS, INC. EXACT (CIK (EXACT))
- SEC filer: INTENSITY THERAPEUTICS, INC. EXACT (CIK (EXACT))
Filings 28
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-10-28 | S-1 | S-1 (registration) | INTENSITY THERAPEUTICS, INC. | 0001213900-21-055138 ↗ |
| 2021-11-12 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-21-058814 ↗ |
| 2021-11-18 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-21-060634 ↗ |
| 2021-12-08 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-21-064145 ↗ |
| 2021-12-09 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-21-064375 ↗ |
| 2022-01-07 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-22-001099 ↗ |
| 2022-04-20 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-22-020664 ↗ |
| 2022-05-16 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-22-027136 ↗ |
| 2022-09-20 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-22-057124 ↗ |
| 2022-10-03 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-22-061060 ↗ |
| 2022-11-02 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-22-068432 ↗ |
| 2023-01-13 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-23-002717 ↗ |
| 2023-01-27 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-23-005668 ↗ |
| 2023-05-18 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-23-041113 ↗ |
| 2023-06-09 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-23-047788 ↗ |
| 2023-06-23 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-23-051151 ↗ |
| 2023-06-29 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001213900-23-052684 ↗ |
| 2023-06-29 | S-1MEF | S-1MEF (added securities) | INTENSITY THERAPEUTICS, INC. | 0001213900-23-053011 ↗ |
| 2023-06-29 | EFFECT | EFFECT (declared effective) | INTENSITY THERAPEUTICS, INC. | 9999999995-23-001911 ↗ |
| 2023-06-30 | 424B4 | 424B4 (final prospectus) | INTENSITY THERAPEUTICS, INC. | 0001213900-23-053470 ↗ |
| 2024-07-11 | EFFECT | EFFECT (declared effective) | INTENSITY THERAPEUTICS, INC. | 9999999995-24-002134 ↗ |
| 2024-07-11 | EFFECT | EFFECT (declared effective) | INTENSITY THERAPEUTICS, INC. | 9999999995-24-002135 ↗ |
| 2024-12-13 | S-1 | S-1 (registration) | INTENSITY THERAPEUTICS, INC. | 0001628280-24-051180 ↗ |
| 2024-12-19 | EFFECT | EFFECT (declared effective) | INTENSITY THERAPEUTICS, INC. | 9999999995-24-003845 ↗ |
| 2025-04-22 | S-1 | S-1 (registration) | INTENSITY THERAPEUTICS, INC. | 0001628280-25-018892 ↗ |
| 2025-04-24 | S-1/A | S-1/A (amendment) | INTENSITY THERAPEUTICS, INC. | 0001628280-25-019491 ↗ |
| 2025-04-24 | EFFECT | EFFECT (declared effective) | INTENSITY THERAPEUTICS, INC. | 9999999995-25-001244 ↗ |
| 2025-04-25 | 424B4 | 424B4 (final prospectus) | INTENSITY THERAPEUTICS, INC. | 0001628280-25-020056 ↗ |
Prospectus pages read 3
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-23 | S-1/A | registration statement | $4.00–$5.00 | $4.00 | 3,250,000 | $13,000,000 | Nasdaq INTS | 2 | primary document; range, price sentence, shares headline, proceeds computed, cover names 2 | document ↗ |
| 2023-06-29 | S-1/A | registration statement | - | - | 0 | primary document; no terms found | document ↗ | |||
| 2023-06-30 | 424B4 | final prospectus | $4.00 | 3,900,000 | $15,600,000 | Nasdaq INTS | 2 | primary document; price sentence, shares sentence, proceeds computed, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Ahlers James M | Officer | Executive VP of CF | 1 | 2023 | |
| BENDER LEWIS H | Director,Officer; Director,Officer,TenPercentOwner | President and CEO | 5 | 2023–2026 | |
| Donovan Daniel | Director | 4 | 2023–2026 | ||
| GOLDBERG MARK A | Director | 4 | 2023–2026 | ||
| Leahy Emer | Director | 4 | 2023–2026 | ||
| Wesolowski John M | Officer | Interim CFO; Principal Accounting Officer; See Remarks | 11 | 2023–2026 | |
| Talamo Joseph | Officer | Chief Financial Officer | 8 | 2023–2026 | |
| DUBIN THOMAS I H | Director | 4 | 2024–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-12-05 | INTENSITY THERAPEUTICS, INC. | Biotechnology | $3,649,483 | $3,649,483 | 1 | 1 |
| 2015-06-12 | Intensity Therapeutics, Inc. | Pharmaceuticals | $5,000,000 | $500,000 | 1 | 1 |
| 2014-02-11 | Intensity Therapeutics, Inc. | Pharmaceuticals | Indefinite | $1,750,000 | 20 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | INTENSITY THERAPEUTICS, INC. | CT | State business registries | name and state |
| Business registration | INTENSITY THERAPEUTICS LLC | CT | State business registries | name and state |
| Form D issuer | INTENSITY THERAPEUTICS, INC. | CT | Form D private offerings | CIK (EXACT) |
| Patent assignee | Intensity Therapeutics, Inc. | CT | Patents (USPTO) | name and state |
| SEC filer | INTENSITY THERAPEUTICS, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Intensity Therapeutics, Inc. | CT | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | INTENSITY THERAPEUTICS INC | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.